Pharma Stocks
-
Germany’s listed cannabis and specialty pharma play
Medios AG operates as a specialty pharmaceuticals group with a focus on niche and high-value medicines, including cannabis-based products. Medios…
Read More » -
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) is back in focus after first quarter 2026 results showed 10% year over year revenue growth to…
Read More » -
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX)
Royalty Pharma plc recently reported first-quarter 2026 results showing revenue of US$631 million and net income of US$295 million, both…
Read More » -
Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap
Amylyx Pharmaceuticals (NasdaqGS:AMLX) is advancing avexitide through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH). Pivotal Phase III…
Read More » -
Is It Time To Reassess Phibro Animal Health (PAHC) After The Recent Share Price Pullback
Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or…
Read More » -
Is It Too Late To Consider Johnson & Johnson (JNJ) After A 46.9% One Year Rally?
Wondering if Johnson & Johnson at around US$222 per share offers good value today, or if most of the opportunity…
Read More » -
Focus on injectable drug packaging growth
SCHOTT Pharma has reported solid first-quarter results driven by demand for injectable drug packaging, with the stock trading near its…
Read More » -
Pharma and tech group eyes growth in US markets
Merck KGaA reports solid Q1 2026 results with growth in its life science and healthcare segments, drawing attention from US…
Read More » -
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After Its 261% One-Year Surge?
Investors may be wondering if Indivior Pharmaceuticals at US$39.60 is still offering value after its strong run, or if most…
Read More » -
Lexicon Pharmaceuticals (LXRX) Quarterly Revenue Drop Reinforces Concerns Over Persistent Losses
Lexicon Pharmaceuticals (LXRX) just closed FY 2025 with fourth quarter revenue of US$5.5 million and a basic EPS loss of…
Read More »